Human recombinant lactoferrin is ineffective in the treatment of human <scp>Helicobacter pylori</scp> infection

Guttner, Yvonne; Windsor, Helen M.; Viiala, Charlie H; Marshall, Barry J.

doi:10.1046/j.1365-2036.2003.01395.x

Cited by 30 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, human recombinant LF (250 or 1000 mg doses, 5 times over a 24 h period) when ingested on its own did not allow eradication of H. pylori in 12 healthy subjects infected with the bacteria [101]. Similar results were reported, also showing no effect of human recombinant LF administration (1000 mg, 5 times for 5 or 14 days) on H. pylori in humans [48]. Consumption of fermented milk has been linked with a reduction in H. pylori infection in humans.…”

Section: Antimicrobialrole Of Milk Proteins In Humanssupporting

confidence: 68%

See 1 more Smart Citation

Bioactive properties of milk proteins in humans: A review

Nongonierma

Fitzgerald

2015

Peptides

View full text Add to dashboard Cite

Many studies have demonstrated that milk protein consumption has benefits in terms of promoting human health. This review assesses the intervention studies which have evaluated potential health enhancing effects in humans following the ingestion of milk proteins. The impact of milk protein ingestion has been studied to asses their satiating, hypotensive, antimicrobial, anti-inflammatory, anticancer, antioxidant, insulinotropic properties as well as their impact on morphological modifications (e.g., muscle and fat mass) in humans. Consistent health promoting effects appear to have been observed in certain instances (i.e., muscle protein synthesis, insulinotropic and hypotensive activity). However, controversial outcomes have also been reported (i.e., antimicrobial, antiinflammatory, anticancer and antioxidant properties). Several factors including interindividual differences, the timing of protein ingestion as well as the potency of the active components may explain these differences. In addition, processing conditions have been reported, in certain instances, to affect milk protein structure and therefore modify their bioactive potential. It is thought that the health promoting properties of milk proteins are linked to the release of bioactive peptides (BAPs) during gastrointestinal digestion. There is a need for further research to develop a more in-depth understanding on the possible mechanisms involved in the observed physiological effects. In addition, more carefully controlled and appropriately powered human intervention studies are required to demonstrate the health enhancing properties of milk proteins in humans.

show abstract

Section: Antimicrobialrole Of Milk Proteins In Humanssupporting

confidence: 68%

“…Milk protein consumption has also been shown to have potential in increasing muscle protein synthesis in humans [32,135]. However, certain human intervention studies have failed to demonstrate health promoting effects following milk protein consumption [48,103].…”

Section: Introductionmentioning

confidence: 99%

Bioactive properties of milk proteins in humans: A review

Nongonierma

Fitzgerald

2015

Peptides

View full text Add to dashboard Cite

show abstract

“…21 Guttner et al administrated 5 g recombinant human LF per day for 5 or 14 days, and found neither conversion of the UBT from positive to negative nor consistent decrease of UBT values with a possible suppression of H. pylori. 22 In contrast to the inefficacy of recombinant human LF, oral administration of bLF (200 mg b.i.d) in combination with a 7-day triple eradication regime (rabeprazole, clarithromycin, and tinidazole) was successful to eradicate H. pylori in 100% of patients, whereas the triple therapy eradication regimen without bLF was only effective in 76.9%. 14 Although there was no conversion of the UBT value from positive to negative (as in the two recombinant human LF studies), administration of the same dosage of bLF alone was effective for reducing the density of H. pylori colonizing the stomach in the present study.…”

Section: Discussionmentioning

confidence: 98%

Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: A randomized, double-blind, placebo-controlled study

Okuda

Nakazawa

Yamauchi

et al. 2005

Journal of Infection and Chemotherapy

View full text Add to dashboard Cite

“…tears, bile and saliva) [116] that showed bacteriostatic and bactericidal effects [117,118] . Human lactoferrin, as a single agent, does not eradicate H. pylori infection as was demonstrated by a recent study performed in vivo in 9 patients [119] . Conversely, bovine lactoferrin could have synergistic actions if employed with PPI and antibiotics as showed in two clinical trials [120,121] .…”

Section: Rescue Therapies After Two or More Failuresmentioning

confidence: 74%

‘Rescue’ Therapies for the Management of <i>Helicobacter pylori </i>Infection

Mario¹,

Cavallaro²,

Scarpignato

2006

Dig Dis

View full text Add to dashboard Cite

Helicobacter pylori infection is the main cause of gastritis, gastroduodenal ulcer and gastric cancer and should be considered as a major public health issue. According to several international guidelines, first-line therapy for treating H. pylori infection consists of proton pump inhibitor (PPI) or ranitidine bismuth citrate (RBC) with any two antibiotics of amoxicillin, clarithromycin or metronidazole given for 7–14 days. However, even with the recommended treatment regimens, approximately 20% of patients will fail to obtain H. pylori eradication. The proportion of patients with first-line H. pylori therapy failure may be higher in clinical practice and it may increase thanks to diffusion of H. pylori treatment. The recommended second-line therapy is the quadruple regimen composed by tetracycline, metronidazole, bismuth salts and a PPI. However, the efficacy of this regimen is limited by poor patient’s compliance due to its side effects, number of tablets per day, and long duration. Moreover, bismuth and metronidazole are not available in all countries. Alternatively, a longer-lasting (i.e. 10–14 days) PPI or RBC triple therapy with two antibiotics has generally been used. In an empirical strategy, the choice of second line depends on the treatment initially used. If a clarithromycin-based regimen was administered in first line, a quadruple regimen or PPI (or RBC) triple therapy with metronidazole and amoxicillin (or tetracycline) should be suggested as a second line. In case of second-line treatment failure, the patient should be evaluated by a case-by-case approach. A susceptibility-guided strategy, if available, is recommended in order to choose the best third-line treatment. Culture can reveal the presence of H. pylori-sensitive strains to clarithromycin (the best effective) or other antimicrobials (such as amoxicillin, metronidazole and tetracycline). Conversely, in an empirical strategy, a third-line not yet used therapy, can reach a high success rate. PPI or RBC, amoxicillin and a new antimicrobial (e.g. rifabutin, levofloxacin or furazolidone) could be used. Several studies have obtained relatively good results with triple therapy combining PPI, rifabutin, and amoxicillin, although a reversible myelotoxicity as leukopenia and thrombocytopenia has been described. Preliminary good results were also achieved with triples PPI regimens combining levofloxacin and amoxicillin without important adverse effects. Furazolidone has also shown efficacy for H. pylori eradication, although untoward reactions could limit its use, especially when high doses are employed. Finally, in more than one H. pylori treatment failure, non-antimicrobial add-on medications (such as lactoferrin, probiotics and others) could be used with the aim either to improve the eradication rate or to minimize side effects.

show abstract

Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection

Cited by 30 publications

References 23 publications

Bioactive properties of milk proteins in humans: A review

Bioactive properties of milk proteins in humans: A review

Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: A randomized, double-blind, placebo-controlled study

‘Rescue’ Therapies for the Management of <i>Helicobacter pylori </i>Infection

Contact Info

Product

Resources

About